Literature DB >> 24797281

Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.

Bilal Hameed1, Neil Mehta, Gonzalo Sapisochin, John P Roberts, Francis Y Yao.   

Abstract

Serum alpha-fetoprotein (AFP) has been increasingly recognized as a marker for a poor prognosis after liver transplantation (LT) for hepatocellular carcinoma (HCC). Many published reports, however, have included a large proportion of patients with HCC beyond the Milan criteria, and the effects of incorporating AFP as an exclusion criterion for LT remain unclear. We studied 211 consecutive patients undergoing LT for HCC within the Milan criteria according to imaging under the Model for End-Stage Liver Disease organ allocation system between June 2002 and January 2009. The majority (93.4%) had locoregional therapy before LT. The median follow-up was 4.5 years (minimum = 2 years). The Kaplan-Meier 1- and 5-year patient survival rates were 94.3% and 83.4%, respectively. In a univariate analysis, significant predictors of HCC recurrence included vascular invasion [hazard ratio (HR) = 10, 95% confidence interval (CI) = 3.9-26, P < 0.001], a pathological tumor stage beyond the University of California San Francisco criteria (HR = 4.1, 95% CI = 1.36-12.6, P = 0.01), an AFP level > 1000 ng/mL (HR = 4.5, 95% CI = 1.3-15.3, P = 0.02), and an AFP level > 500 ng/mL (HR = 3.1, 95% CI = 1.04-9.4, P = 0.04). In a multivariate analysis, vascular invasion was the only significant predictor of tumor recurrence (HR = 5.6, 95% CI = 1.9-19, P = 0.02). An AFP level > 1000 ng/mL was the strongest pretransplant variable predicting vascular invasion (odds ratio = 6.8, 95% CI = 1.6-19.1, P = 0.006). The 1- and 5-year rates of survival without recurrence were 90% and 52.7%, respectively, for patients with an AFP level > 1000 ng/mL and 95% and 80.3%, respectively, for patients with an AFP level ≤ 1000 ng/mL (P = 0.026). Applying an AFP level > 1000 ng/mL as a cutoff would have resulted in the exclusion of 4.7% of the patients fr m LT and a 20% reduction in HCC recurrence. In conclusion, an AFP level > 1000 ng/mL may be a surrogate for vascular invasion and may be used to predict posttransplant HCC recurrence. Incorporating an AFP level > 1000 ng/mL as an exclusion criterion for LT within the Milan criteria may further improve posttransplant outcomes.
© 2014 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24797281      PMCID: PMC4807739          DOI: 10.1002/lt.23904

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  32 in total

1.  Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation.

Authors:  Neil Mehta; Francis Y Yao
Journal:  Liver Transpl       Date:  2013-10       Impact factor: 5.799

Review 2.  Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma.

Authors:  A R Hakeem; R S Young; G Marangoni; J P A Lodge; K R Prasad
Journal:  Aliment Pharmacol Ther       Date:  2012-03-20       Impact factor: 8.171

3.  MELD Exceptions and Rates of Waiting List Outcomes.

Authors:  A B Massie; B Caffo; S E Gentry; E C Hall; D A Axelrod; K L Lentine; M A Schnitzler; A Gheorghian; P R Salvalaggio; D L Segev
Journal:  Am J Transplant       Date:  2011-09-15       Impact factor: 8.086

4.  Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.

Authors:  Pierre-Alain Clavien; Mickael Lesurtel; Patrick M M Bossuyt; Gregory J Gores; Bernard Langer; Arnaud Perrier
Journal:  Lancet Oncol       Date:  2011-10-31       Impact factor: 41.316

5.  Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.

Authors:  Christophe Duvoux; Françoise Roudot-Thoraval; Thomas Decaens; Fabienne Pessione; Hanaa Badran; Tullio Piardi; Claire Francoz; Philippe Compagnon; Claire Vanlemmens; Jérome Dumortier; Sébastien Dharancy; Jean Gugenheim; Pierre-Henri Bernard; René Adam; Sylvie Radenne; Fabrice Muscari; Filomena Conti; Jean Hardwigsen; Georges-Philippe Pageaux; Olivier Chazouillères; Ephrem Salame; Marie-Noelle Hilleret; Pascal Lebray; Armand Abergel; Marilyne Debette-Gratien; Michael D Kluger; Ariane Mallat; Daniel Azoulay; Daniel Cherqui
Journal:  Gastroenterology       Date:  2012-06-29       Impact factor: 22.682

6.  Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.

Authors:  Neil Mehta; Jennifer L Dodge; Aparna Goel; John Paul Roberts; Ryutaro Hirose; Francis Y Yao
Journal:  Liver Transpl       Date:  2013-12       Impact factor: 5.799

7.  Pretransplantation α-fetoprotein slope and milan criteria: strong predictors of hepatocellular carcinoma recurrence after transplantation.

Authors:  Teodora C Dumitra; Sinziana Dumitra; Peter P Metrakos; Jeffrey S Barkun; Prosanto Chaudhury; Marc Deschênes; Steven Paraskevas; Mazen Hassanain; Jean I Tchervenkov
Journal:  Transplantation       Date:  2013-01-15       Impact factor: 4.939

8.  Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma.

Authors:  Kristin Berry; George N Ioannou
Journal:  Liver Transpl       Date:  2013-06       Impact factor: 5.799

9.  Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation.

Authors:  Quirino Lai; Alfonso W Avolio; Ivo Graziadei; Gerd Otto; Massimo Rossi; Giuseppe Tisone; Pierre Goffette; Wolfgang Vogel; Michael B Pitton; Jan Lerut
Journal:  Liver Transpl       Date:  2013-10       Impact factor: 5.799

10.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

Authors:  V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 176.079

View more
  86 in total

1.  Comparison of two equivalent model for end-stage liver disease scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry.

Authors:  Sarah K Alver; Douglas J Lorenz; Kenneth Washburn; Michael R Marvin; Guy N Brock
Journal:  Transpl Int       Date:  2017-08-23       Impact factor: 3.782

2.  Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA.

Authors:  Mohamed Abd El-Fattah
Journal:  Indian J Gastroenterol       Date:  2017-02-14

Review 3.  Diagnosis and treatment of hepatocellular carcinoma: An update.

Authors:  Javier Tejeda-Maldonado; Ignacio García-Juárez; Jonathan Aguirre-Valadez; Adrián González-Aguirre; Mario Vilatobá-Chapa; Alejandra Armengol-Alonso; Francisco Escobar-Penagos; Aldo Torre; Juan Francisco Sánchez-Ávila; Diego Luis Carrillo-Pérez
Journal:  World J Hepatol       Date:  2015-03-27

Review 4.  Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation.

Authors:  Marta Guerrero-Misas; Manuel Rodríguez-Perálvarez; Manuel De la Mata
Journal:  World J Hepatol       Date:  2015-04-08

5.  Milan criteria and its expansions in liver transplantation for hepatocellular carcinoma.

Authors:  Zhijun Zhu
Journal:  Hepatobiliary Surg Nutr       Date:  2016-12       Impact factor: 7.293

6.  Liver transplantation for hepatocellular carcinoma: alpha-fetoprotein should be included in selection criteria.

Authors:  Hans-Christian Pommergaard
Journal:  Transl Gastroenterol Hepatol       Date:  2018-12-11

Review 7.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 8.  Liver Allocation Policies in the USA: Past, Present, and the Future.

Authors:  Anjana Pillai; Thomas Couri; Michael Charlton
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

Review 9.  Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes.

Authors:  Chih-Che Lin; Chao-Long Chen
Journal:  Hepatobiliary Surg Nutr       Date:  2016-10       Impact factor: 7.293

10.  Multicenter Study of Staging and Therapeutic Predictors of Hepatocellular Carcinoma Recurrence Following Transplantation.

Authors:  Theodore H Welling; Kevin Eddinger; Kristen Carrier; Danting Zhu; Tyler Kleaveland; Derek E Moore; Douglas E Schaubel; Peter L Abt
Journal:  Liver Transpl       Date:  2018-09       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.